相关实验视频
Updated: May 6, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
抑制PREX1可以逆转割耐性前列腺癌中恩扎卢胺耐性的作用
Chung Un Lee1, Seon-Yong Yeom2, Wan Song2
1Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea.
酸氨基醇-3,4,5-三酸盐依赖的Rac交换剂1 (PREX1) 驱动了割耐性前列腺癌 (CRPC) 中的恩扎胺耐药性. 向PREX1可能会改善CRPC患者的治疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 抗化前列腺癌 (CRPC) 经常会对恩扎胺治疗产生耐药性.
- 了解酶胺耐药性的分子机制对于改善患者的治疗结果至关重要.
研究的目的:
- 调查CRPC中恩扎拉胺耐药性的机制.
- 探索依赖酸-3,4,5-三酸盐的Rac交换剂1 (PREX1) 在调解CRPC耐药性的作用.
主要方法:
- RNA测序和基因表达造型.
- 细胞增殖,殖民地形成和入侵试验.
- 西方涂抹,蛋白分析和体内瘤异种移植模型.
主要成果:
- 耐酶胺CRPC细胞显示PREX1的调节和癌症迁移通路的激活.
- 通过抑制EGFR信号传递,PREX1敲击降低了细胞增殖,殖民地形成和迁移.
- 在PREX1中断后,瘤生长在体内显著减少.
结论:
- 在CRPC中,PREX1在调解酶胺耐药性方面发挥着关键作用.
- 在CRPC中,PREX1是克服耐药性和提高治疗疗效的潜在治疗标.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
相关概念视频
Abnormal Proliferation
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...